Float Short %

21.94

Margin Of Safety %

Put/Call OI Ratio

0.06

EPS Next Q Diff

-1.63

EPS Last/This Y

3.68

EPS This/Next Y

-2.66

Price

54.2

Target Price

67.92

Analyst Recom

1.23

Performance Q

46.42

Upside

-167.7%

Beta

0.32

Ticker: ANAB

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	ANAB	47.65	0.01	0.00	4460
2026-01-26	ANAB	47.02	0.01	0.00	4462
2026-01-27	ANAB	49.65	0.01	0.07	4463
2026-01-28	ANAB	47.37	0.01	1.49	4492
2026-01-29	ANAB	47.84	0.04	0.00	4657
2026-01-30	ANAB	47.33	0.04	0.40	4662
2026-02-02	ANAB	50.5	0.05	0.62	4703
2026-02-03	ANAB	51.89	0.05	0.00	4699
2026-02-04	ANAB	48.31	0.05	16.25	4698
2026-02-05	ANAB	47.91	0.05	16.25	4698
2026-02-06	ANAB	49.7	0.06	0.25	4763
2026-02-09	ANAB	49.86	0.06	0.00	4765
2026-02-10	ANAB	50.18	0.06	0.00	4775
2026-02-11	ANAB	55.25	0.06	0.00	4775
2026-02-12	ANAB	55.02	0.06	0.10	4786
2026-02-13	ANAB	53.13	0.06	3.44	4777
2026-02-17	ANAB	53.75	0.06	0.00	4793
2026-02-18	ANAB	54.89	0.06	0.00	4788
2026-02-20	ANAB	54.29	0.06	0.05	4826
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	ANAB	47.47	229.7	-26.8	-1.44
2026-01-26	ANAB	47.02	229.7	-26.2	-1.44
2026-01-27	ANAB	49.69	229.7	-28.9	-1.44
2026-01-28	ANAB	47.47	229.7	-24.8	-1.44
2026-01-29	ANAB	47.83	229.7	-27.0	-1.44
2026-01-30	ANAB	47.41	229.7	-26.2	-1.44
2026-02-02	ANAB	50.49	229.7	-29.3	-1.44
2026-02-03	ANAB	51.19	229.7	-27.2	-1.44
2026-02-04	ANAB	48.31	229.7	-40.7	-1.44
2026-02-05	ANAB	47.91	229.7	-43.6	-1.44
2026-02-06	ANAB	49.78	229.7	-46.6	-1.44
2026-02-09	ANAB	49.87	229.7	-44.4	-1.44
2026-02-10	ANAB	50.18	229.7	-44.5	-1.44
2026-02-11	ANAB	55.22	229.7	-50.4	-1.44
2026-02-12	ANAB	54.92	229.7	-43.9	-1.44
2026-02-13	ANAB	53.03	229.7	-42.1	-1.44
2026-02-17	ANAB	53.69	229.7	-44.9	-1.44
2026-02-18	ANAB	54.87	229.7	-45.5	-1.44
2026-02-19	ANAB	55.42	229.7	-	-1.44
2026-02-20	ANAB	54.20	229.7	-	-1.44
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	ANAB	-8.11	-22.74	20.33
2026-01-26	ANAB	-8.11	-24.13	19.92
2026-01-27	ANAB	-8.11	-24.13	19.92
2026-01-28	ANAB	-8.11	-24.13	21.56
2026-01-29	ANAB	-8.11	-24.13	21.56
2026-01-30	ANAB	-8.11	-24.13	21.56
2026-02-02	ANAB	-8.11	-24.17	21.56
2026-02-03	ANAB	-8.11	-24.17	21.56
2026-02-04	ANAB	-8.11	-24.17	21.56
2026-02-05	ANAB	-8.11	-24.17	21.56
2026-02-06	ANAB	-8.11	-24.17	21.56
2026-02-10	ANAB	-8.11	-21.12	21.56
2026-02-11	ANAB	-8.11	-21.12	21.94
2026-02-12	ANAB	-8.11	-21.12	21.94
2026-02-13	ANAB	-8.10	-21.12	21.94
2026-02-17	ANAB	-8.10	-23.59	21.94
2026-02-18	ANAB	-8.10	-23.59	21.94
2026-02-19	ANAB	-8.10	-23.59	21.94
2026-02-20	ANAB	-8.10	-23.59	21.94
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

0.52

Avg. EPS Est. Current Quarter

0.96

Avg. EPS Est. Next Quarter

-1.11

Insider Transactions

-8.1

Institutional Transactions

-23.59

Beta

0.32

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-69.3

Target Price

67.92

P/E

Forward P/E

PEG

P/S

8.85

P/B

P/Free Cash Flow

EPS

-2.82

Average EPS Est. Cur. Y

-1.44

EPS Next Y. (Est.)

-4.1

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-49.94

Relative Volume

0.89

Return on Equity vs Sector %

258.7

Return on Equity vs Industry %

276.2

EPS 1 7Days Diff

EPS 1 30Days Diff

0.35

EBIT Estimation

AnaptysBio, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 136

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

stock quote shares ANAB – AnaptysBio Inc Stock Price stock today

news today ANAB – AnaptysBio Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch ANAB – AnaptysBio Inc yahoo finance google finance

stock history ANAB – AnaptysBio Inc invest stock market

stock prices ANAB premarket after hours

ticker ANAB fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: ANAB

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y